Brolucizumab

Therapeutic indications

Brolucizumab is indicated for:

Neovascular (wet) age-related macular degeneration (AMD)

Population group: only adults (18 years old or older)

Brolucizumab is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

6 mg every 4 weeks with an assessment 16 weeks after treatment start o 6 mg every 6 weeks for the first 2 doses with an assessment 12 weeks after treatment start

Visual impairment due to diabetic macular oedema

Population group: only adults (18 years old or older)

Brolucizumab is indicated in adults for the treatment of visual impairment due to diabetic macular oedema (DME).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

6 mg every 6 weeks for the first 5 doses and thereafter 6 mg every 12 weeks in patients without disease activity and 6 mg every 8 weeks in patients with disease activity

Contraindications

Brolucizumab is contraindicated in the following cases:

Active or suspected ocular or periocular infections

at least one of

Eye infection
Infection of skin of eyelid and periocular region

Active intraocular inflammation

Uveitis

Rhegmatogenous retinal detachment, macular holes

at least one of

Rhegmatogenous retinal detachment
Full thickness macular hole stage III
Full thickness macular hole stage IV

Lactation

Concomitant use of other anti-VEGF

Anti-angiogenic medicinal products

Intraocular surgery within the previous or next 28 days

Surgical procedure

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.